Full View

Patient‐reported outcomes on empagliflozin treatment in glycogen storage disease type Ib: an international questionnaire study

SC Grünert, A Venema, J LaFreniere… - JIMD …, 2023 - Wiley Online Library
In patients with glycogen storage disease type Ib (GSD Ib), quality of life is severely
hampered by neutropenia and neutropenia‐associated symptoms. SGLT2 inhibitors are a …
被引用次数：14 相关文章
[HTML] nih.gov

[HTML][HTML] Patient‐reported outcomes on empagliflozin treatment in glycogen storage disease type Ib: An international questionnaire study

SC Grünert, A Venema, J LaFreniere, B Schneider… - JIMD …, 2023 - ncbi.nlm.nih.gov
In patients with glycogen storage disease type Ib (GSD Ib), quality of life is severely
hampered by neutropenia and neutropenia‐associated symptoms. SGLT2 inhibitors are a …

Patient‐reported outcomes on empagliflozin treatment in glycogen storage disease type Ib: An international questionnaire study

S Grünert, A Venema, J LaFreniere, B Schneider… - JIMD Reports, 2023 - europepmc.org
In patients with glycogen storage disease type Ib (GSD Ib), quality of life is severely
hampered by neutropenia and neutropenia‐associated symptoms. SGLT2 inhibitors are a …

Patient-reported outcomes on empagliflozin treatment in glycogen storage disease type Ib: An international questionnaire study

SC Grünert, A Venema, J LaFreniere, B Schneider… - JIMD Reports, 2023 - research.rug.nl
In patients with glycogen storage disease type Ib (GSD Ib), quality of life is severely
hampered by neutropenia and neutropenia-associated symptoms. SGLT2 inhibitors are a …

Patient-reported outcomes on empagliflozin treatment in glycogen storage disease type Ib: An international questionnaire study.: An international questionnaire study

SC Grünert, A Venema, J LaFreniere, B Schneider… - JIMD …, 2023 - pure.pmu.ac.at
In patients with glycogen storage disease type Ib (GSD Ib), quality of life is severely
hampered by neutropenia and neutropenia-associated symptoms. SGLT2 inhibitors are a …

Patient-reported outcomes on empagliflozin treatment in glycogen storage disease type Ib: An international questionnaire study

SC Grünert, A Venema, J LaFreniere… - JIMD …, 2023 - search.proquest.com
In patients with glycogen storage disease type Ib (GSD Ib), quality of life is severely
hampered by neutropenia and neutropenia-associated symptoms. SGLT2 inhibitors are a …

Patient-reported outcomes on empagliflozin treatment in glycogen storage disease type Ib: An international questionnaire study

SC Grünert, A Venema, J LaFreniere… - JIMD …, 2023 - pubmed.ncbi.nlm.nih.gov
In patients with glycogen storage disease type Ib (GSD Ib), quality of life is severely
hampered by neutropenia and neutropenia-associated symptoms. SGLT2 inhibitors are a …
[PDF] ru.nl

[PDF][PDF] Patient-reported outcomes on empagliflozin treatment in glycogen storage disease type Ib: An international questionnaire study.

SC Grünert, A Venema, J LaFreniere, B Schneider… - 2023 - repository.ubn.ru.nl
In patients with glycogen storage disease type Ib (GSD Ib), quality of life is severely
hampered by neutropenia and neutropenia-associated symptoms. SGLT2 inhibitors are a …

Patient-reported outcomes on empagliflozin treatment in glycogen storage disease type Ib: An international questionnaire study.: An international questionnaire study

SC Grünert, A Venema, J LaFreniere, B Schneider… - JIMD …, 2023 - pure.pmu.ac.at
In patients with glycogen storage disease type Ib (GSD Ib), quality of life is severely
hampered by neutropenia and neutropenia-associated symptoms. SGLT2 inhibitors are a …

Patient-reported outcomes on empagliflozin treatment in glycogen storage disease type Ib: An international questionnaire study.

SC Grünert, A Venema, J LaFreniere, B Schneider… - JIMD Reports, 2023 - europepmc.org
In patients with glycogen storage disease type Ib (GSD Ib), quality of life is severely
hampered by neutropenia and neutropenia-associated symptoms. SGLT2 inhibitors are a …